Similar Papers

Paper Title
Journal
Date
Author
The Combination of Ruxolitinib (RUX) with Decitabine (DAC) in Patients (Pts) with Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia (post-MPN AML): Interim Report of a Phase I/II Trial
Rita Assi ... Farhad Ravandi
Blood | VOL. 130
Rita Assi, et. al.Rita Assi ... Farhad Ravandi
25 Jun 2021
Efficacy, Safety, and Confirmation of the Recommended Phase 2 Starting Dose of the Combination of Ruxolitinib (RUX) and Panobinostat (PAN) in Patients (Pts) with Myelofibrosis (MF)
Claire N Harrison ... Vincent Ribrag
Blood | VOL. 126
Claire N Harrison, et. al.Claire N Harrison ... Vincent Ribrag
03 Dec 2015
Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis
...
Blood | VOL. 134
, et. al. ...
13 Nov 2019
Safety and Efficacy of Combined Ruxolitinib and Decitabine in Patients with Blast-Phase MPN and Post-MPN AML: Results of a Phase I Study (Myeloproliferative Disorders Research Consortium 109 trial)
Raajit K Rampal ...
Blood | VOL. 128
Raajit K Rampal, et. al.Raajit K Rampal ...
02 Dec 2016
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Woyach JA, Burbano GP, Ruppert AS, etal. Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL. Blood. 2024;143(16):1616-1627.
-
Blood | VOL. 145
--
30 Jan 2025
A novel therapy with a rational design for AML.
Maria L Amaya
Blood | VOL. 145
Maria L AmayaMaria L Amaya
30 Jan 2025
For how long has this problem been there?
Niccolò Bolli ... Matteo Claudio Da Vià
Blood | VOL. 145
Niccolò Bolli, et. al.Niccolò Bolli ... Matteo Claudio Da Vià
30 Jan 2025
Targeting CD47: many misses; hopeful for a hit.
Lindsay Wilde ... Margaret Kasner
Blood | VOL. 145
Lindsay Wilde, et. al.Lindsay Wilde ... Margaret Kasner
30 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.